Boston Scientific Corporation (NYSE:BSX) EVP Supratim Bose sold 347,137 shares of the stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total transaction of $10,108,629.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up 0.65% during trading on Thursday, hitting $29.43. 3,702,266 shares of the stock traded hands. The firm has a market cap of $40.38 billion, a price-to-earnings ratio of 52.65 and a beta of 1.09. The stock has a 50 day moving average of $28.14 and a 200 day moving average of $26.94. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $29.50.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the previous year, the company posted $0.27 earnings per share. Boston Scientific Corporation’s revenue for the quarter was up 6.2% on a year-over-year basis. Analysts expect that Boston Scientific Corporation will post $1.26 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Boston Scientific Corporation (BSX) EVP Sells $10,108,629.44 in Stock” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/05/boston-scientific-corporation-bsx-evp-sells-10108629-44-in-stock.html.

A number of large investors have recently made changes to their positions in the business. Lord Abbett & CO. LLC acquired a new position in Boston Scientific Corporation in the second quarter valued at approximately $40,460,000. Sentry Investment Management LLC lifted its holdings in Boston Scientific Corporation by 1.1% in the second quarter. Sentry Investment Management LLC now owns 107,243 shares of the medical equipment provider’s stock valued at $2,973,000 after acquiring an additional 1,125 shares during the period. WFG Advisors LP lifted its holdings in Boston Scientific Corporation by 17.3% in the second quarter. WFG Advisors LP now owns 157,919 shares of the medical equipment provider’s stock valued at $4,378,000 after acquiring an additional 23,305 shares during the period. Toronto Dominion Bank lifted its holdings in Boston Scientific Corporation by 26.1% in the second quarter. Toronto Dominion Bank now owns 463,826 shares of the medical equipment provider’s stock valued at $12,854,000 after acquiring an additional 95,902 shares during the period. Finally, Dynamic Technology Lab Private Ltd lifted its holdings in Boston Scientific Corporation by 80.8% in the second quarter. Dynamic Technology Lab Private Ltd now owns 16,800 shares of the medical equipment provider’s stock valued at $466,000 after acquiring an additional 7,507 shares during the period. 90.44% of the stock is owned by institutional investors.

Several equities analysts have issued reports on the stock. J P Morgan Chase & Co restated an “overweight” rating and set a $31.00 target price (up previously from $27.00) on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada restated a “buy” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a research note on Wednesday, July 12th. Wells Fargo & Company restated an “outperform” rating and set a $31.00 target price (up previously from $29.50) on shares of Boston Scientific Corporation in a research note on Friday, June 16th. Needham & Company LLC upped their target price on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 22nd. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $30.06.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.